user

MEL 100 followed by maintenance therapy with low-dose IL-2 as salvage treatment in multiple myeloma (MM) patients relapsed after standard autologous peripheral blood stem cell transplantation (AuPBSCT).

被引：0
|
作者：
Musto, P [1 ]
Falcone, A [1 ]
Bodenizza, C [1 ]
Sanpaolo, G [1 ]
Carella, AM [1 ]
机构：
[1] Casa Sollievo Sofferenza Hosp, IRCCS, Hematol & Stem Cell Transplantat Unit, San Giovanni Rotondo, Italy
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5365
引用
收藏
页码：395B / 395B
页数：1
相关论文
共 50 条
  • [11] Low dose thalidomide maintenance in myeloma patients after autologous stem cell transplantation
    Bayer, R. -L.
    John, V.
    Devoe, C.
    Cannon, M.
    Klocke, J.
    Gissinger, D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 53 - 54
  • [12] High dose therapy followed by autologous peripheral blood stem cell transplantation as a fist line treatment for multiple myeloma: a Korean multicenter study
    Bang, SM
    Cho, EK
    Suh, C
    Yoon, SS
    Seong, CM
    Cho, KS
    Kang, YG
    Park, S
    Ahn, MJ
    Park, YS
    Oh, D
    Kim, HC
    Jung, CW
    Kim, S
    Lee, JH
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2003, 18 (05) : 673 - 678
  • [13] Thalidomide (THAL) as salvage therapy for relapsed multiple myeloma (MM) after allogeneic stem cell transplantation (SCT).
    Yakoub-agha, I
    Mohty, M
    Attal, M
    Marit, G
    Bulabois, CE
    Sotto, JJ
    Gratecos, N
    Rio, B
    Vernant, JP
    Dib, M
    Garban, F
    Cahn, JY
    Jouet, JP
    Facon, T
    BLOOD, 2003, 102 (11) : 456B - 456B
  • [14] LONG TERM CRYOPRESERVED AUTOLOGOUS BLOOD STEM CELLS FOR SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN RELAPSED MULTIPLE MYELOMA PATIENTS
    Areethamsirikul, N.
    Mashi-Khan, E.
    Winter, A.
    Jimenez-Zepeda, V.
    Reece, D. E.
    Chen, C.
    Trudel, S.
    Tiedemann, R.
    Kukreti, V.
    HAEMATOLOGICA, 2014, 99 : 369 - 369
  • [15] Late effects after autologous peripheral blood stem cell transplantation followed by reduced-intensity allogeneic peripheral blood stem cell transplantation in patients with multiple myeloma
    Zinke-Cerwenka, W
    Eibl, M
    Neumeister, P
    Sill, H
    Linkesch, W
    BONE MARROW TRANSPLANTATION, 2006, 37 : S113 - S113
  • [16] High-dose therapy followed by autologous peripheral blood stem cell transplantation in myeloma associated neuropathy
    Kilidireas, C
    Papadimitriou, C
    Karandreas, N
    Politi, A
    Dimopoulos, M
    JOURNAL OF NEUROLOGY, 2005, 252 : 135 - 135
  • [17] Maintenance treatment after autologous stem cell transplantation in patients with multiple myeloma - new drugs for multiple myeloma
    Maiolino, Angelo
    Garnica, Marcia
    LEUKEMIA RESEARCH, 2018, 73 : S3 - S4
  • [18] Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation
    Fenk, Roland
    Liese, Vanessa
    Neubauer, Florian
    Bruns, Ingmar
    Kondakci, Mustafa
    Balleisen, Sebastian
    Saure, Christian
    Schroeder, Thomas
    Haas, Rainer
    Kobbe, Guido
    LEUKEMIA & LYMPHOMA, 2011, 52 (08) : 1455 - 1462
  • [19] Evaluation of low-dose thalidomide as induction and maintenance therapy in patients with multiple myeloma not eligible for stem cell transplantation
    Aznab, Mozaffar
    Rezaei, Mansour
    Navabi, Jafar
    Moieni, Ali
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (02) : E138 - E143
  • [20] High dose therapy with autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal failure.
    Tummala, R
    Ballester, O
    Janssen, W
    Fields, K
    Hiemenz, J
    Goldstein, S
    Perkins, J
    Rosen, R
    Saez, R
    Elfenbein, G
    EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) : 706 - 706
12345